ASND vs. ARGX, ONC, INSM, BNTX, TEVA, SMMT, GMAB, VTRS, RDY, and QGEN
Should you be buying Ascendis Pharma A/S stock or one of its competitors? The main competitors of Ascendis Pharma A/S include argenex (ARGX), BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry.
Ascendis Pharma A/S vs. Its Competitors
argenx (NASDAQ:ARGX) and Ascendis Pharma A/S (NASDAQ:ASND) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, risk, analyst recommendations and media sentiment.
argenx has a net margin of 40.98% compared to Ascendis Pharma A/S's net margin of -54.94%. argenx's return on equity of 21.06% beat Ascendis Pharma A/S's return on equity.
argenx has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.
argenx currently has a consensus price target of $766.50, suggesting a potential upside of 8.87%. Ascendis Pharma A/S has a consensus price target of $243.36, suggesting a potential upside of 25.51%. Given Ascendis Pharma A/S's higher possible upside, analysts clearly believe Ascendis Pharma A/S is more favorable than argenx.
In the previous week, argenx had 36 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 49 mentions for argenx and 13 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 1.44 beat argenx's score of 0.77 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.
argenx has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.
60.3% of argenx shares are held by institutional investors. 2.4% of argenx shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
argenx beats Ascendis Pharma A/S on 12 of the 17 factors compared between the two stocks.
Get Ascendis Pharma A/S News Delivered to You Automatically
Sign up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ASND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ascendis Pharma A/S Competitors List
Related Companies and Tools
This page (NASDAQ:ASND) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access